Employees: 162
Size Alebund Pharmaceuticals (Jiangsu) (9637.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $595M, the 701st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$19.95 on 18 Nov 2026.
Growth Revenue grew 673.9% over the last twelve months (peer median +14.5%); the operating margin is -494.9% (peer median -28.7%).
Valuation It trades at 26.8× enterprise value to sales against a peer median of 3.4× (4th most expensive of 16).
Capital Return on invested capital runs 89.4 points below its cost of capital (5.5% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | HK$139M | HK$33.1M | HK$7.07M | HK$0 |
| Revenue growth | — | +368% | — | — |
| Gross profit | HK$69.5M | -HK$29.8M | -HK$9.87M | -HK$12.8M |
| EBITDA | -HK$636M | -HK$653M | -HK$323M | -HK$399M |
| Net income | -HK$778M | -HK$813M | -HK$353M | -HK$403M |
| Free cash flow | -HK$479M | -HK$443M | -HK$537M | -HK$552M |
| Capital expenditure | HK$80.7M | HK$110M | HK$257M | HK$222M |
| Total debt | n/a | HK$612M | HK$510M | HK$203M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9637.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.3% | -15.3% | 4th highest of 21 |
| Distance from 52-week high | -57.4% | -44.8% | 7th lowest of 21 |
| Revenue growth (TTM) | +673.9% | +14.5% | 3rd highest of 17 |
| Operating margin | -494.9% | -28.7% | 3rd lowest of 17 |
| EV / Sales | 26.8× | 3.4× | 4th most expensive of 16 |
| ROIC minus cost of capital | -89.4 pp | -9.3 pp | 3rd lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | 26.8× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | 3.2× | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | 1,794.8× | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 11.0× | 39.8% | +143.5% |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 3.4× | 31.9% | +27.2% |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 2.3× | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | 2.2× | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 2.3× | 14.3% | +15.4% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |